H P Greisler
Overview
Explore the profile of H P Greisler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brewster L, Ucuzian A, Brey E, Liwanag M, Samarel A, Greisler H
J Cell Physiol
. 2010 May;
225(2):562-8.
PMID: 20506497
Pathological vascular smooth muscle cell (VSMC) behavior after vascular interventions such as angioplasty or bypass is initiated within the 3D environment of the vessel media. Here VSMCs proliferate, invade the...
2.
Brewster L, Brey E, Greisler H
Adv Drug Deliv Rev
. 2006 Jun;
58(4):604-29.
PMID: 16769148
Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the...
3.
Tassiopoulos A, Greisler H
J Biomater Sci Polym Ed
. 2001 Mar;
11(11):1275-84.
PMID: 11263813
Both cardiovascular implants and therapeutic interventions on native arteries fail due to biologic responses occurring at the blood/prosthesis/arterial wall and tissue/prosthesis/arterial wall interfaces, resulting in the failure modes of thrombosis...
4.
Xue L, Tassiopoulos A, Woloson S, Stanton Jr D, Ms C, Hampton B, et al.
J Vasc Surg
. 2001 Mar;
33(3):554-60.
PMID: 11241127
Objective: Cardiovascular tissue engineering approaches to vessel wall restoration have focused on the potent but relatively nonspecific and heparin-dependent mesenchymal cell mitogen fibroblast growth factor 1 (FGF-1). We hypothesized that...
5.
Littooy F, Steffen G, Greisler H, Kang S, Mansour M, Chmura C
J Surg Res
. 2000 Dec;
95(1):32-6.
PMID: 11120632
We have taken the short stay approach to carotid artery surgery to our VA setting over the past 5 to 6 years. Retrospectively, we reviewed the efficacy and safety of...
6.
Xue L, Shireman P, Hampton B, Burgess W, Greisler H
J Surg Res
. 2000 Jul;
92(2):255-60.
PMID: 10896831
Background: The structure/function relationships of fibroblast growth factor 1 (FGF-1) are being investigated using site mutation, yielding novel structures with potential clinical applicability for modulating tissue responses to vascular interventions....
7.
Shireman P, Greisler H
J Vasc Surg
. 2000 May;
31(5):936-43.
PMID: 10805884
Purpose: Fibrin glue (FG) has been used for local cytokine delivery on both vascular grafts and angioplasty sites. We measured the diffusive release of vascular endothelial growth factor (VEGF) and...
8.
Shireman P, Xue L, Maddox E, Burgess W, Greisler H
J Vasc Surg
. 2000 Feb;
31(2):382-90.
PMID: 10664506
Objective: Site-directed mutagenesis is an important technique that can alter cytokine function, thereby eliciting desired responses. S130K is a mutation of fibroblast growth factor-1 (FGF-1), with lysine replacing serine in...
9.
Fox D, Kouris G, Blumofe K, Heilizer T, Husak V, Greisler H
J Surg Res
. 1999 Aug;
86(1):9-16.
PMID: 10452862
Background: The fluorescent marker PKH26 has been demonstrated to be useful for the tracking of endothelial cells in short-term studies; however, the optimal labeling conditions for long-term implants have not...
10.
Shireman P, Hampton B, Burgess W, Greisler H
J Vasc Surg
. 1999 May;
29(5):852-61; discussion 862.
PMID: 10231637
Purpose: Fibrin glue (FG) has been used as a delivery system for bioactive agents on grafts and angioplasty sites. Reports from two different institutions suggest that heparin concentrations of 500...